PARP1 and prostate cancer: Blockade of AR function leads to reduced expression of several HR-associated genes such as BRCA1, RAD54L and RMI2, so that sequential treatment of a prostate cancer xenograft with the AR antagonist, enzalutamide, and the PARP-1 inhibitor, olaparib, strongly suppresses tumor growth [89].